MOLM-13 acute myeloid leukemia cell line (MOLM-13) (MOLM-13)

MOLM-13 is a human acute myeloid leukemia (AML) cell line established from the peripheral blood of a 20-year-old male patient with AML (FAB M5a) at relapse, following a prior diagnosis of myelodysplastic syndrome (MDS) [1, 3, 9]. It is a widely utilized in vitro and in vivo model for studying AML pathogenesis and evaluating the efficacy of novel therapeutic agents [1, 5]. The cell line is molecularly characterized by the presence of the Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutation and the MLL-AF9 (KMT2A-MLLT3) fusion protein, both of which are key drivers of leukemogenesis and poor clinical prognosis [2, 3, 11, 12]. Due to its high sensitivity to FLT3 inhibition, MOLM-13 is frequently employed in the preclinical development of drugs such as midostaurin, quizartinib, and gilteritinib [2, 4, 6]. Additionally, it serves as a model for investigating mechanisms of drug resistance, such as the acquisition of secondary FLT3 mutations or microenvironment-mediated survival [8, 13, 14].

Other names

MOLM13MOLM-13 cell lineMOLM-13 AML cell line

FLT3 inhibition [2, 4, 5], DNA synthesis inhibition [12], JAK2 inhibition [5], CDK4 inhibition [8], and MDM2 inhibition [2, 4].